A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

Study Site BEL004, Antwerp

Study Site BEL003, Brussels

Study Site BEL002, Ghent

Study Site BEL001, Leuven

Study Site BGR001, Sofia

Study Site DEU001, Berlin

Study Site DEU002, Essen

Study Site GRC001, Thessaloniki

Study Site NLD002, Amsterdam

Study Site NLD001, Utrecht

Study Site SRB001, Belgrade

Study Site SWE001, Gothenburg

Study Site SWE002, Stockholm

Study Site GBR003, Birmingham

Study Site GBR004, Glasgow

Study Site GBR005, Liverpool

Study Site GBR006, Newcastle

Study Site GBR001, Papworth Everard

Study Site GBR002, Wythenshawe

Study Site GBR007, London